The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 9, 2013, Pages 1612-1619

  Hubbard, Rebecca A ^a,b   Johnson, Eric ^a   Hsia, Raymond ^c   Rutter, Carolyn M ^a,b  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Group Health Permanente   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; TUMOR INVASION;

AGED; AGED, 80 AND OVER; ANIMALS; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD;

EID: 84884145848     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0254     Document Type: Article

References (25)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2008 incidence and mortality web-based report; 2012 [cited 2012 Jun 13]. Available from: http://www.cdc.gov/uscs.
2. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007;1:CD001216.
3. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecaloccult- blood test. Lancet 1996;348: 1467-71.
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348: 1472-7.
5. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328: 1365-71.
6. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150: 1-8.
7. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149: 638-58.
8. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134: 1570-95.
9. US Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149: 627-37.
10. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334: 155-9.
11. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99: 1462-70.
12. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149: 659-69.
13. Fisher DA, Grubber JM, Castor JM, Coffman CJ. Ascertainment of colonoscopy indication using administrative data. Dig Dis Sci 2011; 55: 1721-5.
14. Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat 1972;34: 187-220.
15. Hubbard R, Miglioretti D. A semiparametric censoring bias model for estimating the cumulative risk of a false-positive screening test under dependent censoring. Biometrics 2013;69: 245-53.
16. Gelfand AE, Smith AF. Sampling-based approaches to calculating marginal densities. J Am Stat Assoc 1990;85: 398-409.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18: 695-706.
18. Doubeni CA, Laiyemo AO, Reed G, Field TS, Fletchers RH. Socioeconomic and racial patterns of colorectal cancer screening among medicare enrollees in 2000 to 2005. Cancer Epidemiol Biomarkers Prev 2009;18: 2170-5.
19. Klabunde CN, Cronin KA, Breen N, Waldron WR, Ambs AH, Nadel MR. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 2011;20: 1611-21.
20. SEER. SEER stat fact sheets: colon and rectum 2013 [cited 2013 May 23]. Available from: http://seer.cancer.gov/statfacts/html/colorect. html.
21. Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010;55: 1637-42.
22. Bini EJ, Rajapaksa RC, Weinshel EH. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 2005;100: 1586-92.
23. Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, et al. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care 2008;46:S91-6.
24. Fenton JJ, Elmore JG, Buist DS, Reid RJ, Tancredi DJ, Baldwin LM. Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med 2010;8: 397-401.
25. Seeff LC, Nadel MR, Klabunde CN, Thompson T, Shapiro JA, Vernon SW, et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004;100: 2093-103.